Characterization of Ax Adenosine Receptors in Atrial and Ventricular Myocardium From Diseased Human Hearts

The purpose of the present study was to characterize adenosine receptors in human atrial and ventricular myocardium. In isolated electrically driven preparations, adenosine produced „direct” negative inotropic effects in atrial myocardium (AT). In ventricular myocardium (VE), it only had negative Inotropic properties when force of contraction had been stimulated with isoprenaline (“indirect” effect), but it has no inotropic effect alone. The adenosine receptor antagonist 8-phenyltheophylline antagonized the „direct” and „indirect” effects; these findings indicated that both effects were mediated by adenosine receptors. In cardiac membranes from human AT and VE, adenosine receptors were characterized with [3H]-8-cyclopentyl-l,3-dipropylxanthine (DPCPX) binding. The effects of agonists. R-(-)-N6-phenylisopropyladenosinc (R-PIA), S-(+)-N6-phenylisopropyladenosuie (S-PIA), and 5′-(N-ethylcarboxamido)adenosine (NECA) and the effects of guanine nucleotides [Gpp(NH)p] were studied also. The antagonist affinities as judged from the apparent affinity, Kd, of [3H] DPCPX were similar in AT (2.2 nmol/1; 95% confidence limits, 1.4–3.7) and VE (1.8 nmol/1; 95% confidence limits, 1.0–3.0). The number of adenosine receptors was 1.7 times greater in AT (26.9 ± 2.33 fmol/mg protein; n =5) than in VE (16.2 ± 23 fmol/mg protein; n =5). High and low affinity states of adenosine receptors evaluated with the influence of Gpp(NH)p on agonist competition with R-PIA were similar in AT or VE. The rank orders of potency for agonists (R-PIA>S-PIA>NECA) and antagonists (DPCPX>8-phenyltheophylline>theophylline) were characteristic for the A, receptor subtype. It is concluded that A, adenosine receptors exist in the human myocardium. Since binding properties were similar in AT and VE, the same A1 adenosine receptor probably couples to different effectors in a similar guanine nucleotide-dependent way. [3H] DPCPX is the first radiolabeled antagonist ligand that allows detection of A, adenosine receptors and their coupling in the human myocardium.

[1]  M. Lohse,et al.  [3H] 8 ‐Cyclopentyl‐1,3 ‐dipropylxanthine Binding to A1 Adenosine Receptors of Intact Rat Ventricular Myocytes , 1988, Circulation research.

[2]  W. Baumgartner,et al.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. , 1988, The Journal of clinical investigation.

[3]  M. Böhm,et al.  Adenosine inhibits the positive inotropic effect of 3‐isobutyl‐1‐methylxanthine in papillary muscles without effect on cyclic AMP or cyclic GMP , 1988, British journal of pharmacology.

[4]  E. Leung,et al.  Characterization of cardiac A1 adenosine receptors by ligand binding and photoaffinity labeling. , 1988, The Journal of pharmacology and experimental therapeutics.

[5]  M. Böhm,et al.  Functional evidence for the existence of adenosine receptors in the human heart. , 1985, European journal of pharmacology.

[6]  W. Schmitz,et al.  Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a role of cyclic AMP and cyclic GMP. , 1985, The Journal of pharmacology and experimental therapeutics.

[7]  J. Linden,et al.  The Mechanism by Which Adenosine and Cholinergic Agents Reduce Contractility in Rat Myocardium: Correlation with Cyclic Adenosine Monophosphate and Receptor Densities , 1985, Circulation research.

[8]  J. Linden,et al.  [125I]Aminobenzyladenosine, a new radioligand with improved specific binding to adenosine receptors in heart. , 1985, Circulation research.

[9]  W. Schütz,et al.  Adenosine receptors in the heart: controversy about signal transmission , 1985 .

[10]  D. Middlemiss,et al.  Adenosine receptors in the heart: controversy about signal transmission , 1985 .

[11]  T. Kenakin.  Schild regressions as indicators of non-equilibrium steady-states and heterogeneous receptor populations , 1985 .

[12]  R. D. Green,et al.  Inhibitory adenosine receptors in the heart: characterization by ligand binding studies and effects on beta-adrenergic receptor stimulated adenylate cyclase and membrane protein phosphorylation. , 1984, Journal of molecular and cellular cardiology.

[13]  B. Haubitz,et al.  Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. , 1984, The Journal of pharmacology and experimental therapeutics.

[14]  A. Watt.  HYPERTROPHIC CARDIOMYOPATHY: A DISEASE OF IMPAIRED ADENOSINE-MEDIATED AUTOREGULATION OF THE HEART , 1984, The Lancet.

[15]  S. Grossman,et al.  Increased myocardial adenosine release in heart failure. , 1984, Journal of molecular and cellular cardiology.

[16]  Paton Dm.  Classification of adenosine receptors. , 1984 .

[17]  A. Gilman.  G proteins and dual control of adenylate cyclase , 1984, Cell.

[18]  D. Paton.  Classification of adenosine receptors. , 1984, Methods and findings in experimental and clinical pharmacology.

[19]  G. Isenberg,et al.  Isolated atrial myocytes: adenosine and acetylcholine increase potassium conductance. , 1983, The American journal of physiology.

[20]  J. Dobson.  Mechanism of Adenosine Inhibition of Catecholamine‐ Induced Responses in Heart , 1983, Circulation research.

[21]  C. Johnston,et al.  Demonstration of adenylate cyclase coupled adenosine receptors in guinea pig ventricular membranes. , 1983, Biochemical and biophysical research communications.

[22]  N. Taira,et al.  Modification by Islet‐Activating Protein of Direct and Indirect Inhibitory Actions of Adenosine on Rat Atrial Contraction in Relation to Cyclic Nucleotide Metabolism , 1983, Journal of cardiovascular pharmacology.

[23]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[24]  R. Lefkowitz,et al.  Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. , 1982, Molecular pharmacology.

[25]  W. Schütz,et al.  Evidence against adenylate cyclase-coupled adenosine receptors in the guinea pig heart. , 1981, European journal of pharmacology.

[26]  O. Hazeki,et al.  Modification by islet-activating protein of receptor-mediated regulation of cyclic AMP accumulation in isolated rat heart cells. , 1981, The Journal of biological chemistry.

[27]  G. Baumann,et al.  Inhibitory Action of Adenosine on Histamine‐ and Dopamine‐Stimulated Cardiac Contractility and Adenylate Cyclase in Guinea Pigs , 1981, Circulation research.

[28]  J. E. McKenzie,et al.  Myocardial adenosine and coronary resistance during increased cardiac performance. , 1980, The American journal of physiology.

[29]  J. Dobson,et al.  Inhibition by adenosine of catecholamine-induced increase in rat atrial contractility. , 1980, The American journal of physiology.

[30]  D. Cooper,et al.  Subclasses of external adenosine receptors. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Margarete Müller,et al.  Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells , 1978, Nature.

[32]  J. Dobson.  Reduction by Adenosine of the Isoproterenol‐ Induced Increase in Cyclic Adenosine3′,5′‐Monophosphate Formation and Glycogen Phosphorylase Activity in Rat Heart Muscle , 1978, Circulation research.

[33]  G. Reed,et al.  Release of adenosine from human hearts during angina induced by rapid atrial pacing. , 1974, The Journal of clinical investigation.

[34]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.

[35]  Edward A. Johnson,et al.  Effect of Acetylcholine and Adenosine on Cardiac Cellular Potentials , 1956, Nature.

[36]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.